Your browser doesn't support javascript.
Potential of antibody pair targeting conserved antigenic sites in diagnosis of SARS-CoV-2 variants infection.
Wang, Siling; Wu, Yangling; Wang, Yizhen; Chen, Zihao; Ying, Dong; Lin, Xue; Liu, Chang; Lin, Min; Zhang, Jinlei; Zhu, Yuhe; Guo, Shaoqi; Shang, Huixian; Chen, Xiuting; Qiang, Hongsheng; Yin, Yifan; Tang, Zimin; Zheng, Zizheng; Xia, Ningshao.
  • Wang S; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China.
  • Wu Y; Emergency Department, The First Affiliated Hospital of Xiamen University, 361003 Xiamen, Fujian, PR China.
  • Wang Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China.
  • Chen Z; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China.
  • Ying D; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China.
  • Lin X; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China.
  • Liu C; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China.
  • Lin M; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China.
  • Zhang J; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China.
  • Zhu Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China.
  • Guo S; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China.
  • Shang H; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China.
  • Chen X; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China.
  • Qiang H; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China.
  • Yin Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China.
  • Tang Z; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China. Electronic address: zimintang@xmu.edu.cn.
  • Zheng Z; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China. Electronic address: zhengzizheng@xmu.edu.cn
  • Xia N; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, 361102 Xiamen, Fujian, PR China. Electronic address: nsxia@xmu.edu.cn.
J Virol Methods ; 309: 114597, 2022 Nov.
Article in English | MEDLINE | ID: covidwho-1966905
ABSTRACT
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has become disaster for human society. As the pandemic becomes more regular, we should develop more rapid and accurate detection methods to achieve early diagnosis and treatment. Antigen detection methods based on spike protein has great potential, however, it has not been effectively developed, probably due to the torturing conformational complexity. By utilizing cross-blocking data, we clustered SARS-CoV-2 receptor binding domain (RBD)-specific monoclonal antibodies (mAbs) into 6 clusters. Subsequently, the antigenic sites for representative mAbs were identified by RBDs with designed residue substitutions. The sensitivity and specificity of selected antibody pairs was demonstrated using serial diluted samples of SARS-CoV-2 S protein and SARS-CoV S protein. Furthermore, pseudovirus system was constructed to determine the detection capability against SARS-CoV-2 and SARS-CoV. 6 RBD-specific mAbs, recognizing different antigenic sites, were identified as potential candidates for optimal antibody pairs for detection of SARS-CoV-2 S protein. By considering relative spatial position, accessibility and conservation of corresponding antigenic sites, affinity and the presence of competitive antibodies in clinical samples, 6H7-6G3 was rationally identified as optimal antibody pair for detection of both SARS-CoV-2 and SARS-CoV. Furthermore, our results showed that 6H7 and 6G3 effectively bind to SARS-CoV-2 variants of concern (VOCs). Taken together, we identified 6H7-6G3 antibody pair as a promising rapid antigen diagnostic tool in containing COVID-19 pandemic caused by multiple VOCs. Moreover, our results also provide an important reference in screening of antibody pairs detecting antigens with complex conformation.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / COVID-19 Type of study: Diagnostic study / Prognostic study / Randomized controlled trials Topics: Variants Limits: Humans Language: English Journal: J Virol Methods Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / COVID-19 Type of study: Diagnostic study / Prognostic study / Randomized controlled trials Topics: Variants Limits: Humans Language: English Journal: J Virol Methods Year: 2022 Document Type: Article